Genmab A/S
GMAB
$25.85
-$0.51-1.94%
NASDAQ
| 12/31/2025 | 06/30/2025 | 03/31/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.03% | 18.74% | 18.57% | 18.57% | 49.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.03% | 18.74% | 18.57% | 18.57% | 49.47% |
| Cost of Revenue | 52.71% | 103.57% | 55.56% | 55.56% | 191.61% |
| Gross Profit | 0.33% | 15.58% | 16.84% | 16.84% | 45.60% |
| SG&A Expenses | 5.99% | 11.63% | 0.80% | 0.80% | 45.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.87% | 9.07% | 8.21% | 8.21% | 56.57% |
| Operating Income | -29.97% | 37.93% | 62.07% | 62.07% | 37.27% |
| Income Before Tax | -90.07% | 37.79% | -2.01% | -2.01% | 281.00% |
| Income Tax Expenses | 200.09% | -16.35% | -14.04% | -14.04% | -154.64% |
| Earnings from Continuing Operations | -94.64% | 65.52% | 1.56% | 1.56% | 469.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.64% | 65.52% | 1.56% | 1.56% | 469.38% |
| EBIT | -29.97% | 37.93% | 62.07% | 62.07% | 37.27% |
| EBITDA | -30.60% | 37.27% | 58.73% | 58.73% | 36.77% |
| EPS Basic | -94.47% | 72.70% | 3.38% | 3.38% | 485.60% |
| Normalized Basic EPS | -46.73% | 31.98% | 13.26% | 13.26% | 273.24% |
| EPS Diluted | -94.44% | 73.16% | 3.74% | 3.74% | 486.15% |
| Normalized Diluted EPS | -47.43% | 32.33% | 13.67% | 13.67% | 273.14% |
| Average Basic Shares Outstanding | -3.06% | -4.16% | -1.76% | -1.76% | -2.77% |
| Average Diluted Shares Outstanding | -1.76% | -4.42% | -2.10% | -2.10% | -2.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |